



BIODIEM LTD

ABN 20 096 845 993

Level 4,

100 Albert Rd,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.biodiem.com

Announcement

Wholesale Investor – Singapore Capital Expo and Small Cap Showcase Presentation

Melbourne, 10 November 2014:

BioDiem's CEO, Julie Phillips presented at the Singapore Capital Expo and Small Cap Showcase held at the Singapore Convention & Exhibition Centre, in Singapore on Friday 7 November 2014. The Showcase event was designed to strengthen the capital links and cooperation throughout the Southeast Asia region, creating the next centre of emerging growth companies and a stage for innovation. The BioDiem presentation focused on BioDiem's BDM-I and the opportunity presented by the antimicrobial for collaboration and investment.

ENDS

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. For additional information, please visit www.biodiem.com

Further information

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email jphillips@biodiem.com